ADVANCED ENDOMETRIAL CARCINOMA
Clinical trials for ADVANCED ENDOMETRIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ENDOMETRIAL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED ENDOMETRIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with endometrial cancer that had returned or spread. The goal was to see if the combination could slow or stop cancer growth. Participants had already tried other treatments and their cancer ha…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:42 UTC
-
New combo attack on Hard-to-Treat cancers shows early promise
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:35 UTC
-
New combo therapy targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially bladder cancer. The main goals are to find the safest dose and understand side effects. About 7…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:34 UTC
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:09 UTC